SUPN vs. PCRX, INVA, CORT, ARQT, OCUL, ORIC, PHAT, KPTI, BTAI, and PRGO
Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Pacira BioSciences (PCRX), Innoviva (INVA), Corcept Therapeutics (CORT), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Karyopharm Therapeutics (KPTI), BioXcel Therapeutics (BTAI), and Perrigo (PRGO). These companies are all part of the "medical" sector.
Pacira BioSciences (NASDAQ:PCRX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.
Pacira BioSciences currently has a consensus target price of $49.50, indicating a potential upside of 81.92%. Supernus Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 32.99%. Given Supernus Pharmaceuticals' higher possible upside, research analysts clearly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.
Pacira BioSciences has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals.
In the previous week, Pacira BioSciences had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 7 mentions for Pacira BioSciences and 5 mentions for Supernus Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.00 beat Supernus Pharmaceuticals' score of -0.28 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.
Pacira BioSciences received 336 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 71.73% of users gave Pacira BioSciences an outperform vote.
Pacira BioSciences has a net margin of 6.22% compared to Pacira BioSciences' net margin of 0.22%. Supernus Pharmaceuticals' return on equity of 12.81% beat Pacira BioSciences' return on equity.
99.7% of Pacira BioSciences shares are owned by institutional investors. 6.6% of Pacira BioSciences shares are owned by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Pacira BioSciences beats Supernus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Supernus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Supernus Pharmaceuticals Competitors List
Related Companies and Tools
